...
首页> 外文期刊>Journal of Medical Virology >Prevalence of amino acid mutation in hepatitis C virus core region among Japanese volunteer blood donors.
【24h】

Prevalence of amino acid mutation in hepatitis C virus core region among Japanese volunteer blood donors.

机译:日本自愿献血者中丙型肝炎病毒核心区域的氨基酸突变患病率。

获取原文
获取原文并翻译 | 示例

摘要

It is not known whether there is a trend of increasing or decreasing incidence of new hepatitis C virus (HCV) infections in Japan. From the treatment point of view, it is important to verify HCV genotypes and the prevalence of treatment-resistant clones of HCV. At the Japanese Red Cross blood centers, all blood samples obtained from blood donation have been screened using serological methods and the minipool nucleic acid amplification testing. One hundred and fourteen donors have been identified over the past 10 years to be HCV RNA-only positive without detectable anti-HCV and were considered to be in the acute phase of HCV infection. There was a trend of decreasing incidence of such new infections among the blood donors. HCV RNA-only-positive samples were examined further for genotyping and HCV RNA quantitation. Genotype 2 (2a plus 2b) was predominant (78.2%) among them followed by genotype 1b (21.2%). Direct sequencing was carried out to detect the possible treatment-resistant mutant clones 70Q and 91M, clones with amino acid substitutions at positions 70 and 91 of the HCV core protein, respectively. 70Q and 91M were found regularly in donors with genotype 1b, but not in those with other genotypes. No particular endemic areas for the mutant clones were identified. There was no significant difference in the mean viral titer between the 70Q mutant type and the non-70Q wild-type. Even in newly infected people, the mutant clone 70Q was detected frequently.
机译:在日本,是否存在增加或减少新的丙型肝炎病毒(HCV)感染率的趋势尚不清楚。从治疗的角度来看,重要的是要验证HCV基因型和HCV耐治疗性克隆的普遍性。在日本红十字会血液中心,使用血清学方法和minipool核酸扩增测试筛选了从献血中获得的所有血液样本。在过去的十年中,已经确定了114个供体为HCV RNA阳性,而没有可检测到的抗HCV,被认为处于HCV感染的急性期。在献血者中,这种新感染的发生率呈下降趋势。进一步检查仅HCV RNA阳性样品的基因型和HCV RNA定量。其中基因型2(2a加2b)占主要地位(78.2%),其次是基因型1b(21.2%)。进行直接测序以检测可能的抗治疗突变体克隆70Q和91M,这些克隆分别在HCV核心蛋白的70和91位具有氨基酸取代。在基因型1b的供体中定期发现70Q和91M,而在其他基因型的供体中则没有。没有确定突变克隆的特定流行区域。 70Q突变型和非70Q野生型之间的平均病毒滴度没有显着差异。即使在新感染的人群中,也经常检测到突变克隆70Q。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号